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Introduction. Primary hyperparathyroidism (PHP) is characteristically determined by high levels of calcium and high or
inappropriate levels of parathyroid hormone (PTH). Technological advances have dramatically changed the surgical technique
overtheyearsonceintraoperativeparathyroidhormone(IOPTH)assayhadallowedforfocusedapproaches. Objective.T oeval uat e
our 10-year experience in employing a rapid intraoperative PTH assay for PHP. Methods. A prospective cohort of 91 PHP-
operated patients in a tertiary institution in S˜ ao Paulo, Brazil, from June 2000 to April 2011. Results. We had 85 (93.4%) successful
parathyroidectomies, 6 (6.6%) failed parathyroidectomies in 91 previous unexplored patients, and 5 (100%) successful remedial
surgeries. The IOPTH was true-positive in 88.5%, true-negative in 7.3%, false-positive in 2.1%, and false-negative in 2.1% of
the procedures. IOPTH was able to obviate additional exploration or to ask for additional exploration in 92 (95.8%) procedures.
Conclusion. The IOPTH revealed to be an important technological adjunct in the current parathyroid surgery for PHP.
1.Introduction
Primary hyperparathyroidism (PHP) is a hypercalcemic dis-
ease stemming from an abnormal increase in parathyroid
hormone (PTH) secretion by one or more parathyroid
glands. The hallmark of this condition is the presence of
high levels of calcium and high or inappropriate levels of
PTH. Primary hyperparathyroidism is more common in
womenthaninmenandincreaseswithaginginbothgenders
[1]. Since primary hyperparathyroidism was ﬁrst described,
surgery remains the only deﬁnitive therapy [2]. The goal
of parathyroidectomy is the excision of the abnormal
parathyroid gland(s), preserving the normal ones in order to
achieve and maintain a postoperative normocalcemic state
[3]. Success rates for surgical treatment depend on the skill
and experience of the surgeon in ﬁnding and recognizing
the pathologic changes and excising the correct amount of
hyperfunctioning parathyroid tissue [4].
T h es u r g i c a lt r e a t m e n to fP H Ph a su n d e r g o n es u b s t a n -
tive changes since the ﬁrst successful parathyroidectomy was
performed by Felix Mandl in 1925 [5]. It is now expected
that the vast majority of patients will be cured during initial
surgical exploration at a low probability of morbidity. The
conventional time-honored operation employing general
endotracheal anesthesia and bilateral cervical exploration is
safe and eﬀective when performed by experienced surgeons.
However, recent technical innovations, including improved
preoperative localization and availability of rapid intraoper-
ative PTH assays (IOPTH), have yielded focused approaches
with excellent outcomes.
Sporadic primary hyperparathyroidism is caused by a
single enlarged parathyroid gland (parathyroid adenoma)
in approximately 85% of the cases, whereas multigland
hyperplasia occurs in 15% and parathyroid carcinoma is
found in less than 1% of patients. Unlike the previous
dogma that required surgical identiﬁcation of both enlarged
and normal parathyroid glands, the current paradigm in
many centers is to identify and excise the incident enlarged
gland and to conﬁrm operative cure, employing a rapid
intraoperative PTH assay. Due to the relatively short half-life2 Journal of Osteoporosis
of PTH (4-5min), a dramatic drop in circulating hormone
can be detected once the abnormally secreting gland or
glands have been removed [6]. A curative drop in PTH
allows the surgeon to terminate the operation and obviate
additional exploration, whereas failure of the PTH levels
to demonstrate an adequate decrement asks for additional
exploration because of the presence of presumed additional
hypersecreting gland(s).
T h ea i mo ft h ep r e s e n ts t u d yw a st oe v a l u a t eo u r1 0 - y e a r
experienceinemployingarapidintraoperativePTHassayfor
PHP.
2. Patientsand Methods
2.1. Study Design. This is a prospective study on a cohort of
operated patients treated at a university referral center.
This investigation was approved by the UNIFESP/EPM
Ethics Committee.
2.2. Patients. From June 2000 to April 2011, 96 surgeries for
PHP were performed at Hospital S˜ ao Paulo UNIFESP/EPM,
S˜ ao Paulo, Brazil. These 96 procedures were performed in
91 previous unexplored patients who had at least 6 months
of postoperative follow-up with enough reported data to
be eligible for the study. The remaining 5 were remedial
procedures.
The PHP diagnoses were established in the presence of
high levels of calcium and high or inappropriate levels of
PTH.
All patients had their age, gender, symptoms (bone
and kidney), preoperative localization tests, serum ionized
calcium (iCa), serum total calcium and intact PTH recorded
before parathyroidectomy, as well as IOPTH dosages. The
laboratorial tests were repeated 1 month, 6 months, and in
1-year increments after surgery.
2.3. Methods. A series of 91 consecutive patients with pri-
mary hyperparathyroidism underwent parathyroidectomy
guided by intraoperative PTH at Federal University of S˜ ao
Paulo,Brazil,fromJune2000toApril2011.Focusedparathy-
roidectomy guided by intraoperative PTH was the initial
procedure when preoperative localization tests were positive
and when there were no suspicion of malignant disease. A
bilateral cervical exploration guided by intraoperative PTH
was performed when preoperative localization tests were
negative.
A baseline peripheral venous blood sample was obtained
just after anesthesia induction as well as 10 minutes after
the abnormal parathyroid tissue removal. The intraoperative
criterion used to predict successful parathyroidectomy was
a decrease in the intact PTH levels exceeding 50% from
the preincision hormone level [7]. If this criterion was met,
surgical exploration of the neck would be completed and
the incision closed. Otherwise, further surgical exploration
o ft h en e c kw o u l dh a v et ob ec a r r i e do n .
Intraoperative PTH was measured using Elecsys PTH
Immunoassay (Elecsys 1010 System, Roche, Mannheim,
Germany). The test is an immunometric assay based on
Table 1: Demographic, clinical, and biochemical aspects in 91
patients, with PHP.
Variable
Patients 91
Age, mean (range) y 54 (12–80)
Gender, N◦.( % )
Male 18 (19.8)
Female 73 (80.2)
Symptoms, N◦.( % )
none 13 (14.3)
Kidney stones 47 (51.6)
Osteoporosis 37 (40.7)
Pathologic bone fracture 4 (4.4)
Renal disease related to PHP 4 (4.4)
Biochemical
iCa, mean (range) mmol/L 1.64 (1.37–2.50)
tCa, mean (range) mg/dL 12.0 (10.5–19.3)
iPTH, mean (range) pg/dL 425.6 (74–2605)
Reference: iCa: 1.15–1.32mmol/L; tCa: 8.5–10.5mg/dL; PTH 11–65pg/dL.
monoclonal antibodies, magnetic particles as solid phase,
and ruthenium complex as chemiluminescent label. Total
time to perform the assay is 9 minutes; reference values
are 10–65pg/mL. To validate the rapid PTH assay, 170
samples from the study were also measured using a standard
immunoﬂuorimetric assay (IFMA) [8].
The IOPTH accuracy calculation was based on the
following deﬁnitions: a true-positive (TP) result of IOPTH
wasdeﬁnedasthecorrectpredictionofpostoperativenormal
calcium levels for at least 6 months; true negative (TN)
was the correct prediction of incomplete excision by either
resection of an additional gland(s) or operative failure; false
positive (FP) was the incorrect prediction of normocalcemia
with subsequent postoperative persistent hypercalcemia and
high PTH levels; false negative (FN) was the incorrect
prediction of incomplete excision followed by postoperative
normocalcemia.
We considered cured patients that presented normo-
calcemia along the postoperative follow-up. Persistent dis-
ease was considered when serum calcium and PTH levels
remained above normal range just after surgery. Recurrence
was deﬁned when, after reaching normocalcemic levels,
serum calcium and intact PTH measurements start to rise
to abnormal values at least 6 months after surgery.
Serum Ionized calcium (1.15–1.32mmol/L), serum total
calcium (8.5–10.5mg/dL) and intact PTH (11–67pg/mL),
were measured using standard automatic assays.
3. Results
The demographic, clinical, and biochemical aspects of 91
patients with PHP are shown in Table 1.
Among all cohort of 91 patients, 69 (75.8%) had solitary
adenoma, 10 (11.0%) had Multiple Endocrine Neoplasia
Type 1 (MEN1), 6 (6.6%) had double adenomas, 4 (4.4%)Journal of Osteoporosis 3
Table 2: Outcomes in 91 PHP patients.
Variable Operative
success
Operative
failure
Total 85 6
Solitary adenoma 69 0
Double adenoma 4 2
MEN1 8 2
Carcinoma 3 1
Waiting for remedial surgery (MGD) 1 1
Biochemical
iCa, mean (range) mmol/L 1.64
(1.35–2.50)
1.68
(1.51–2.06)
tCa, mean (range) mg/dL 12.0
(10.5–19.3)
12.0
(10.6–13.4)
iPTH, mean (range) pg/dL 431.5
(80–2605)
332.0
(74–1155)
Intraoperative results
IOPTH mean decay (range)% 80.5
(34.3–96.0)
50.5
(32.4–84.1)
IOPTH true-positive, N◦ (%) 80 (87.9) 0
IOPTH true-negative, N◦, (%) 3 (3.3) 4 (4.4)
IOPTH false-positive, N◦,( % ) 0 2( 2 . 2 )
IOPTH false-negative, N◦, (%) 2 (2.2) 0
had carcinomas, and 2 (2.2%) patients are still waiting for
remedial surgery for multiglandular disease (MGD), 1 of
whom had recurrence disease after 10 years of follow-up
and the other persistent disease after a false positive IOPTH
(Table 2).
We had 85 (93.4%) successful parathyroidectomies 6
(6.6%)failedparathyroidectomiesin91previousunexplored
patients, and 5 (100%) successful remedial surgeries. Among
the 85 successful patients, 69 (81.2%) had solitary adenoma,
3 (3.5%) had carcinoma, 4 (4.7%) had double adenomas, 8
(9.4%) had MEN1, and 1 (1.2%) still has MGD (Table 2).
The mean decay of IOPTH in the successful group of
patients was 80.5% (34.3% to 96.0%). In these 85 patients,
we had 80 TP results (67 adenomas, 3 carcinomas, 8 MEN1
and2recurrences—theselasttwopatientsshowninTable 3).
We also had 3 cases of double adenoma in which the IOPTH
resulted in a TN value, requiring additional exploration to
prevent persistent disease (Table 2). There were only 2 FN
results among the successful group patients (Table 4). The
mean decay of IOPTH in the 80 patients with TP results was
81.7%, with a minimum drop of 55.0% (55.0% to 96.0%).
Operative failure of the initial surgery occurred in 6
patients: 2 Double Adenoma, 2 MEN1, 1 Carcinoma, and 1
MGDwhoisstillwaitingforremedialsurgery(Table 5).Both
cases of Double Adenoma had a TN decay of IOPTH, but the
second adenoma wasnot found during the initial operation.
With the aid of new localization exams, successful remedial
operations were performed with an IOPTH TP result.
The patient with parathyroid carcinoma developed
hypercalcemia and high levels of PTH two months after
surgery. In search of distant metastasis, this patient under-
went a pulmonary computerized tomography and multiple
pulmonary nodules were found. For this reason, she was
classiﬁed as IOPTH false-positive.
In both MEN1 patients, the IOPTH showed an incom-
plete resection of all hyperfunctioning parathyroid tissue
with TN results. One patient already had MEN1 diagnosis at
the time of initial surgery and we failed to ﬁnd the fourth
gland. The other patient was ﬁrst operated as a solitary
adenoma and MEN1 diagnosis surfaced just in the follow-
up.
There was only one case in the operative failure patients;
the IOPTH had an FP result (Table 4).
4. Discussion
The surgical treatment for primary PHP has undergone
some changes in recent years, evolving from the standard
bilateral neck exploration technique to a less time-con-
suming procedure of unilateral neck exploration. Taking
into account the increasing number of asymptomatic and/or
oligosymptomatic primary hyperparathyroidism diagnosis
in the recent years, the need for a safe and less time-
consuming procedure with low perioperative morbidity is
clear. Preoperative parathyroid localization imaging study
and IOPTH are essential components of the focused
parathyroidectomy that allow the excision of all abnormal
parathyroid glands without the examination of the normally
secretingglands[9].TheclinicalutilityofrapidIOPTHmea-
surements in parathyroidectomy was ﬁrst reported in 1988
using a modiﬁed intact PTH IRMA assay [10]. Since then,
rapid assays have been developed by means of radioactive
[4, 11, 12]a sw e l la sn o n r a d i o a c t i v ef o r m a t s[ 12, 13]. The
predominance of a solitary adenoma disease in 85% to 96%
ofcasesofPHPandtheshorthalf-lifeofintactPTH(1–84)of
only 1.4 to 4 minutes [14–20] combined with the remaining
suppressed normal parathyroid glands after removal of
all hyperfunctioning tissue [15] allows the measurement
of IOPTH to evaluate its decline rates. Several studies
have demonstrated the utility of IOPTH monitoring in
the treatment of single-gland primary hyperparathyroidism
[3, 8, 21–27]. Most experts agree that IOPTH assay is the
most useful intraoperative adjunct to assist the surgeon in
PHP surgical treatment [28, 29]. It is worth highlighting
the useful employment of preoperative localization imaging
study in conjunction with IOPTH: the former points out
where the surgeon should start exploration from, and the
latter assures that hypersecretory parathyroid tissue removal
was accomplished.
The current usual criteria for IOPTH measurement
describe a decrease of 50% or over from either the baseline
(preincision) [7] or the highest preincision or preexcision
[24] value within 10 minutes following hyperfunctioning
parathyroid resection, pointing out surgical cure and pre-
dicting normocalcemia [30]. By resorting to those criteria,
highaccuracyin intraoperative prediction ofcureisachieved
[30]. Mostly for practice and cost reasons, we have used just
two samples as our criteria since we started making use of
the IOPTH: the preincision and 10 minutes postexcision of
hyperfunctioning parathyroid.4 Journal of Osteoporosis
Table 3: Recurrence cases among the successful true-positive IOPTH patients.
Patient
Initial surgery
Follow-up IOPTH
result
Remedial
Follow-up Diagnosis Ultra
sound
Sesta
mibi
N◦
glands
excised
IOPTH
decay
Ultra
sound
Sesta
mibi
N◦
glands
excised
IOPTH
decay
F, 59y Neg Right 1 88.4 Recurrence at
48 months TP Left Left 1 78.4 12 Double
adenoma
F, 52y Neg Left 1 80.5 Recurrence at
118 months TP Right Right Waiting remedial surgery MGD
Table 4: False results of IOPTH.
Patient
Biochemical Localization tests Surgical
ﬁndings
IOPTH
Decision IOPTH results
tCa iCa PTH Ultrasound Sestamibi Preinc Postex Decay
M, 40y 12.6 1.94 455 Right Right Cystic Adenoma 798 524 34.3% Rupture of the cyst FN
F, 62y 12.8 1.68 181 Neg Left Solitary
Adenoma 209 116 44.5% Bilateral dissection
with 3 normal glands FN
F, 59y 10.6 1.52 159 Right Right Solitary
Adenoma 216 106 50.9% End of procedure FP
F, 62y 13.4 2.60 2800 Right Right Carcinoma 2480 394 84.1% End of procedure FP
Preinc: preincision; postex: postexcision; FN: false-negative; FP: false-positive.
Table 5: Cases of operative failure.
Patient
Initial surgery Remedial
Follow-up Diagnosis Ultra
sound
Sesta
mibi
N◦ glands
excised
IOPTH
decay
IOPTH
result
Ultra
sound Sesta mibi N◦ glands
excised
IOPTH
decay
M, 26y Left Neg 1 42.4 TN Right neg 1 89.4 126 Doubl´ e
Adenoma
F, 38y Neg Neg 1 32.4 TN Right neg 1 89.4 54 Doubl´ e
Adenoma
F, 32y Neg Right 1 33.5 TN 3 70.3 78 MEN1
M, 22y Neg Neg 3 51.6 TN Right 1 85.4 84 MEN1
F, 62y Right Right 1 84.1 FP 36 Carcinoma
F, 59y Right Right 1 50.9 FP Neg waiting remedial surgery MGD
Neg: negative; TP: true positive; TN: true negative; FP: false positive; MGD: multiple glandular disease; MEN1: multiple endocrine neoplasia type 1.D e c a y
values are in %; follow-up period in months.
Our series of 96 PHP consecutive surgeries over 10
years reﬂects a complex tertiary referral center and has its
limitations.Thedataaresubjecttoselectionandreferralbias.
Most of these patients were referred speciﬁcally due to their
severe signs/symptoms and comorbid medical conditions,
which are related to their high bone and kidney disease and
the 4.4% incidence of carcinoma. Furthermore, all patients
were ﬁrst evaluated by an endocrinologist group specialized
in osteometabolic disease who elected the patients for
surgical treatment, reﬂecting the 11% incidence of MEN1
and the absence of familial hypocalciuric hypercalcemia case
in our surgical series.
The PHP diagnose has not been made in a routine prac-
tice in most Brazilian centers, and many patients have their
diagnoses made just after severe signs/symptoms. We have
noticed an increase in the percentage of asymptomatic
patients over the years in the number of PHP cases [31],
but probably such increase has not been enough to raise the
number of our small solitary adenomas (78.3%).
We get an inferior number of successful parathyroidec-
tomy (93.4%) in previous unexplored patients compared
to some large series [9, 32], but it can be considered a
satisfactory result, taking into account the high number
of patients with carcinoma and MEN1 in our series. On
the other hand, we have obtained good results (100%) in
5 successful second surgical explorations so far: ﬁrst, we
removed a second adenoma in three patients (two persistent
and one recurrent disease); second, we were able to remove
a not found fourth gland in a MEN1 patient, and ﬁnally, we
removed three glands in a MEN1 patient previous operated
as an sporadic PHP.
In our series of 91 patients, IOPTH had true results in
87 patients (95.6%). However, considering our 96 surgical
procedures (5 remedial surgeries), IOPTH was able toJournal of Osteoporosis 5
obviate or to ask for additional exploration because of the
presence of presumed additional hypersecreting gland(s) in
92 (95.8%) procedures.
The IOPTH had a mean decay of 81.7% in the TP
patients, and the minimum drop in our series that results
i np a t i e n tc u r e( o p e r a t i v es u c c e s s )w a s5 5 . 0 % .W eh a do n l y
4 IOPTH false results, 2 FP and 2 FN.
The 2 FN results were followed by unnecessary bilateral
neck dissection. One of these cases occurred in a ruptured
parathyroid cystic adenoma that may have resulted in
a substantial elevation of the hormone levels after the
preincision sample, and it should be related to an inadequate
IOPTH decay [19]. The second patient had the others three
parathyroidglandsidentiﬁedinnormalconditions.Basedon
such scenario, surgical procedure was ended and the patient
evolved with normocalcemia.
One FP case occurred in a patient with concordant
preoperative localization tests. The IOPTH decay was 50.9%,
dropping from 216pg/dL to 106pg/dL. As observed by other
authors, the FP cases are usually represented by a marginal
PTH level decrease with a ﬁnal PTH level above the normal
range [9]. For these reasons, stricter criteria for the IOPTH
dynamics have been suggested, such as the return of the 10-
minute PTH to within normal range [7]. However, these
stricter criteria were estimated to increase the operative
success only by 0.3% [9], with signiﬁcant increase in the false
negativeresults,bringing onmore unnecessarybilateralneck
dissection [9, 33]. Using these stricter criteria in our patients
would have brought about 21 (24.7%) unnecessary bilateral
dissections, and just one additional diagnose.
We classiﬁed a patient with parathyroid carcinoma that
revealed metastatic pulmonary disease two months after
surgery as an FP result because she certainly had metastatic
disease at the surgery and IOPTH (84.1% decay) failed to
predict the presence of presumed additional hypersecreting
tissue. However, it can be controversial to suppose that
IOPTH has failed in this patient, once IOPTH was not
deﬁned to predict distant disease.
All 4 patients with parathyroid carcinoma had very
suggestive signals of malignant disease at presentation (very
high PTH levels, severe hypercalcemia and palpable neck
mass) and were not elected to the focused approach. They
were submitted to an “en bloc” tumor resection, removing
the parathyroid tumor, the ipsilateral thyroid lobe, and the
lymph nodes related to a central neck dissection.
Duringthefollow-upperiod,2(2.1%)patientspresented
PHP recurrence, 48 months and 118 months after initial
parathyroidectomy. One patient removed a second adenoma
and had a successful remedial surgery with IOPTH decay of
78.4%. The second patient recurrence occurred almost 10
years after initial surgery and is still waiting for remedial
surgery. Udelsman et al. [32] published a large series of 1,650
PHP patients and found 5 (0.3%) recurrent cases. Other
authors have published higher recurrence rates, reaching up
to 4.1% [34]. The reason of this recurrence phenomenon is
yet to be further explored. One of our series limitations is
the absence of vitamin D dosages, one important factor that
should be related to the genesis of PHP recurrence.
5. Conclusion
The IOPTH revealed to be an important technological ad-
j u n c ti nt h ec u r r e n tp a r a t h y r o i ds u r g e r yf o rP H P .
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